TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To determine if the combined incidence of nonfatal myocardial infarction and coronary heart disease death differs between diuretic-based and each of three alternative antihypertensive pharmacological treatments. Also, to determine, in a subset of this population, if lowering serum cholesterol with a HMG CoA reductase inhibitor in older adults reduces all-cause mortality compared to a control group receiving usual care. Conducted in conjunction with the Department of Veterans' Affairs.


Options:
A: Intervention Type: DRUG; Name: Inhibitors, ACE; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: amlodipine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: lisinopril; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: doxazosin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: chlorthalidone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: pravastatin; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olmesartan medoxomil | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Calcium channel blockers (amlodipine, azelnidipine) | Intervention Type: DRUG; Name: Olmesartan medoxomil; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Calcium channel blockers (amlodipine, azelnidipine); Assigned to Arm(s): 2
C: Arm Label: Valsartan; Type: ACTIVE_COMPARATOR; Interventions: Drug: Valsartan | Arm Label: Amlodipine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amlodipine | Intervention Type: DRUG; Name: Valsartan; Assigned to Arm(s): Valsartan | Intervention Type: DRUG; Name: Amlodipine; Assigned to Arm(s): Amlodipine
D: Intervention Type: DRUG; Name: Valsartan + amlodipine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Valsartan + HCTZ; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Amlodipine + HCTZ; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Valsartan + amlodipine + HCTZ; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To determine if the combined incidence of nonfatal myocardial infarction and coronary heart disease death differs between diuretic-based and each of three alternative antihypertensive pharmacological treatments. Also, to determine, in a subset of this population, if lowering serum cholesterol with a HMG CoA reductase inhibitor in older adults reduces all-cause mortality compared to a control group receiving usual care. Conducted in conjunction with the Department of Veterans' Affairs.


Options:
A: Intervention Type: DRUG; Name: Inhibitors, ACE; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: amlodipine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: lisinopril; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: doxazosin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: chlorthalidone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: pravastatin; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A
B: Arm Label: Fosinopril,benidipine combination; Type: EXPERIMENTAL; Interventions: Drug: Fosinopril, Drug: Benidipine | Arm Label: Fosinopril,hydrochlorothiazide combination; Type: EXPERIMENTAL; Interventions: Drug: Fosinopril, Drug: Hydrochlorothiazide | Intervention Type: DRUG; Name: Fosinopril; Assigned to Arm(s): Fosinopril,benidipine combination, Fosinopril,hydrochlorothiazide combination | Intervention Type: DRUG; Name: Benidipine; Assigned to Arm(s): Fosinopril,benidipine combination | Intervention Type: DRUG; Name: Hydrochlorothiazide; Assigned to Arm(s): Fosinopril,hydrochlorothiazide combination
C: Arm Label: OM40/AML10; Type: EXPERIMENTAL; Interventions: Drug: Olmesartan medoxomil, Drug: Amlodipine | Arm Label: OM40/HCTZ25; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olmesartan medoxomil, Drug: Hydrochlorothiazide | Arm Label: AML10/HCTZ25; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amlodipine, Drug: Hydrochlorothiazide | Arm Label: OM40/AML10/HCTZ25; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olmesartan medoxomil, Drug: Amlodipine, Drug: Hydrochlorothiazide | Intervention Type: DRUG; Name: Olmesartan medoxomil; Assigned to Arm(s): OM40/AML10, OM40/AML10/HCTZ25, OM40/HCTZ25 | Intervention Type: DRUG; Name: Amlodipine; Assigned to Arm(s): AML10/HCTZ25, OM40/AML10, OM40/AML10/HCTZ25 | Intervention Type: DRUG; Name: Hydrochlorothiazide; Assigned to Arm(s): AML10/HCTZ25, OM40/AML10/HCTZ25, OM40/HCTZ25
D: Arm Label: Valsartan; Type: ACTIVE_COMPARATOR; Interventions: Drug: Valsartan | Arm Label: Amlodipine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amlodipine | Intervention Type: DRUG; Name: Valsartan; Assigned to Arm(s): Valsartan | Intervention Type: DRUG; Name: Amlodipine; Assigned to Arm(s): Amlodipine

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To test the hypothesis that low-dose inhaled nitric oxide administered to preterm infants who continue to require mechanical ventilation at 14 days of age will reduce the incidence of chronic lung disease.


Options:
A: Intervention Type: PROCEDURE; Name: mechanical ventilation; Assigned to Arm(s): N/A
B: Arm Label: Inhaled Nitric Oxide (iNO); Type: EXPERIMENTAL; Interventions: Drug: Inhaled Nitric Oxide (iNO) | Arm Label: Nitrogen (placebo); Type: PLACEBO_COMPARATOR; Interventions: Drug: Nitrogen (placebo) | Intervention Type: DRUG; Name: Inhaled Nitric Oxide (iNO); Assigned to Arm(s): Inhaled Nitric Oxide (iNO) | Intervention Type: DRUG; Name: Nitrogen (placebo); Assigned to Arm(s): Nitrogen (placebo)
C: Arm Label: Inhaled Nitric Oxide (INO); Type: ACTIVE_COMPARATOR; Interventions: Drug: Nitric oxide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Nitric oxide; Assigned to Arm(s): Inhaled Nitric Oxide (INO) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Inhaled Nitric Oxide (iNO); Type: EXPERIMENTAL; Interventions: Drug: iNO | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: iNO; Assigned to Arm(s): Inhaled Nitric Oxide (iNO) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To test if early revascularization, primarily with angioplasty (PTCA) or bypass surgery (CABG), reduced all-cause in-hospital mortality from cardiogenic shock compared to conventional treatment, including thrombolysis.


Options:
A: Intervention Type: PROCEDURE; Name: angioplasty, transluminal, percutaneous coronary; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: coronary artery bypass; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: thrombolytic therapy; Assigned to Arm(s): N/A
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Levosimendan; Type: EXPERIMENTAL; Interventions: Drug: Levosimendan | Intervention Type: DRUG; Name: Levosimendan; Assigned to Arm(s): Levosimendan | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: L; Type: EXPERIMENTAL; Interventions: Drug: levosimendan | Arm Label: P; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: levosimendan; Assigned to Arm(s): L | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): P
D: Intervention Type: DEVICE; Name: Intra-aortic balloon pump counterpulsation; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To determine whether the addition of angiotensin converting enzyme (ACE) inhibitor to standard therapy in patients with known coronary artery disease and preserved left ventricular function will prevent cardiovascular mortality and reduce the risk of myocardial infarction.


Options:
A: Intervention Type: DRUG; Name: Telmisartan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Combination of Telmisartan and Ramipril; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Ramipril; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: candesartan cilexetil; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: angiotensin-converting enzyme inhibitors; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Benazepril; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To determine the effects, in postmenopausal women, of hormone replacement therapy on progression/regression of coronary heart disease, as measured by quantitative angiography.


Options:
A: Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Micronized 17B-estradiol; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Hormone replacement therapy; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estradiol; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: medroxyprogesterone; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To determine the effects, in postmenopausal women, of hormone replacement therapy on progression/regression of coronary heart disease, as measured by quantitative angiography.


Options:
A: Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estradiol; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: medroxyprogesterone; Assigned to Arm(s): N/A
B: Arm Label: Previous HT use and cognition; Type: N/A; Interventions: N/A
C: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Conjugated equine estrogens 0.45 mg/day, Drug: Transdermal estradiol, 50 mcg/day, Drug: Micronized progesterone, 200 mg/day x 12 d/month, Drug: CEE, progesterone, transdermal patch or the placebo | Arm Label: Arm 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: CEE , progesterone, estradiol patch or placebo for each, Drug: CEE, progesterone, transdermal patch or the placebo | Intervention Type: DRUG; Name: Conjugated equine estrogens 0.45 mg/day; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Transdermal estradiol, 50 mcg/day; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Micronized progesterone, 200 mg/day x 12 d/month; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: CEE , progesterone, estradiol patch or placebo for each; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: CEE, progesterone, transdermal patch or the placebo; Assigned to Arm(s): Arm 1, Arm 2
D: Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Childhood Asthma Management Program
Brief Summary: The purpose of this study is to evaluate the long term effects of anti-inflammatory therapy compared to bronchodilator therapy on the course of asthma, particularly on lung function and bronchial hyperresponsiveness, and on physical and psychosocial growth and development.


Options:
A: Arm Label: 1 Budesonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Budesonide | Arm Label: 2 Nedocromil; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nedocromil | Arm Label: 3 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3 Placebo | Intervention Type: DRUG; Name: Nedocromil; Assigned to Arm(s): 2 Nedocromil | Intervention Type: DRUG; Name: Budesonide; Assigned to Arm(s): 1 Budesonide
B: Arm Label: I; Type: EXPERIMENTAL; Interventions: Behavioral: Feedback of patient adherence information | Arm Label: II; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Active control group | Intervention Type: BEHAVIORAL; Name: Feedback of patient adherence information; Assigned to Arm(s): I | Intervention Type: BEHAVIORAL; Name: Active control group; Assigned to Arm(s): II
C: Intervention Type: DRUG; Name: ciclesonide; Assigned to Arm(s): N/A
D: Arm Label: Salmeterol/ fluticasone propionate Diskus® inhaler 50/100 mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol/ fluticasone propionate Diskus® inhaler 50/100 mcg | Arm Label: fluticasone propionate 2 x 100 mcg; Type: OTHER; Interventions: Drug: fluticasone propionate 2 x 100 mcg | Intervention Type: DRUG; Name: Salmeterol/ fluticasone propionate Diskus® inhaler 50/100 mcg; Assigned to Arm(s): Salmeterol/ fluticasone propionate Diskus® inhaler 50/100 mcg | Intervention Type: DRUG; Name: fluticasone propionate 2 x 100 mcg; Assigned to Arm(s): fluticasone propionate 2 x 100 mcg

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Childhood Asthma Management Program
Brief Summary: The purpose of this study is to evaluate the long term effects of anti-inflammatory therapy compared to bronchodilator therapy on the course of asthma, particularly on lung function and bronchial hyperresponsiveness, and on physical and psychosocial growth and development.


Options:
A: Intervention Type: DRUG; Name: Pulmicort (budesonide) pMDI; Assigned to Arm(s): N/A
B: Arm Label: 1 Budesonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Budesonide | Arm Label: 2 Nedocromil; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nedocromil | Arm Label: 3 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3 Placebo | Intervention Type: DRUG; Name: Nedocromil; Assigned to Arm(s): 2 Nedocromil | Intervention Type: DRUG; Name: Budesonide; Assigned to Arm(s): 1 Budesonide
C: Arm Label: Daily ICS + Rescue ICS; Type: EXPERIMENTAL; Interventions: Drug: Beclomethasone dipropionate, Drug: Albuterol sulfate | Arm Label: Daily ICS; Type: ACTIVE_COMPARATOR; Interventions: Drug: Beclomethasone dipropionate, Drug: Albuterol sulfate | Arm Label: Rescue ICS; Type: EXPERIMENTAL; Interventions: Drug: Beclomethasone dipropionate, Drug: Albuterol sulfate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Albuterol sulfate | Intervention Type: DRUG; Name: Beclomethasone dipropionate; Assigned to Arm(s): Daily ICS, Daily ICS + Rescue ICS | Intervention Type: DRUG; Name: Beclomethasone dipropionate; Assigned to Arm(s): Daily ICS + Rescue ICS, Rescue ICS | Intervention Type: DRUG; Name: Albuterol sulfate; Assigned to Arm(s): Daily ICS, Daily ICS + Rescue ICS, Placebo, Rescue ICS
D: Intervention Type: DRUG; Name: beclomethasone/salbutamol combination; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: beclomethasone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: salbutamol; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Childhood Asthma Management Program
Brief Summary: The purpose of this study is to evaluate the long term effects of anti-inflammatory therapy compared to bronchodilator therapy on the course of asthma, particularly on lung function and bronchial hyperresponsiveness, and on physical and psychosocial growth and development.


Options:
A: Arm Label: Ciclesonide 40 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide, Drug: Placebo, Drug: Salbutamol | Arm Label: Ciclesonide 80 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide, Drug: Placebo, Drug: Salbutamol | Arm Label: Ciclesonide 160 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide, Drug: Placebo, Drug: Salbutamol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Salbutamol | Intervention Type: DRUG; Name: Ciclesonide; Assigned to Arm(s): Ciclesonide 160 µg, Ciclesonide 40 µg, Ciclesonide 80 µg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Ciclesonide 160 µg, Ciclesonide 40 µg, Ciclesonide 80 µg, Placebo | Intervention Type: DRUG; Name: Salbutamol; Assigned to Arm(s): Ciclesonide 160 µg, Ciclesonide 40 µg, Ciclesonide 80 µg, Placebo
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ciclesonide; Assigned to Arm(s): 1, 2, 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4
C: Arm Label: Daily ICS + Rescue ICS; Type: EXPERIMENTAL; Interventions: Drug: Beclomethasone dipropionate, Drug: Albuterol sulfate | Arm Label: Daily ICS; Type: ACTIVE_COMPARATOR; Interventions: Drug: Beclomethasone dipropionate, Drug: Albuterol sulfate | Arm Label: Rescue ICS; Type: EXPERIMENTAL; Interventions: Drug: Beclomethasone dipropionate, Drug: Albuterol sulfate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Albuterol sulfate | Intervention Type: DRUG; Name: Beclomethasone dipropionate; Assigned to Arm(s): Daily ICS, Daily ICS + Rescue ICS | Intervention Type: DRUG; Name: Beclomethasone dipropionate; Assigned to Arm(s): Daily ICS + Rescue ICS, Rescue ICS | Intervention Type: DRUG; Name: Albuterol sulfate; Assigned to Arm(s): Daily ICS, Daily ICS + Rescue ICS, Placebo, Rescue ICS
D: Arm Label: 1 Budesonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Budesonide | Arm Label: 2 Nedocromil; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nedocromil | Arm Label: 3 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3 Placebo | Intervention Type: DRUG; Name: Nedocromil; Assigned to Arm(s): 2 Nedocromil | Intervention Type: DRUG; Name: Budesonide; Assigned to Arm(s): 1 Budesonide

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To reduce episodes of first time stroke by 75 percent in children with sickle cell anemia by the administration of prophylactic transfusion therapy.


Options:
A: Arm Label: Stem Cell Transplantation; Type: EXPERIMENTAL; Interventions: Procedure: Stem cell transplantation | Arm Label: Transfusion program; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Transfusion program | Intervention Type: PROCEDURE; Name: Stem cell transplantation; Assigned to Arm(s): Stem Cell Transplantation | Intervention Type: PROCEDURE; Name: Transfusion program; Assigned to Arm(s): Transfusion program
B: Arm Label: Standard Therapy: Observation; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Hydroxyurea; Type: EXPERIMENTAL; Interventions: Drug: Hydroxyurea | Intervention Type: DRUG; Name: Hydroxyurea; Assigned to Arm(s): Hydroxyurea
C: Intervention Type: PROCEDURE; Name: blood transfusion; Assigned to Arm(s): N/A
D: Arm Label: Transfusion Group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: transfusion therapy | Arm Label: Observation Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: transfusion therapy; Assigned to Arm(s): Transfusion Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To reduce episodes of first time stroke by 75 percent in children with sickle cell anemia by the administration of prophylactic transfusion therapy.


Options:
A: Intervention Type: PROCEDURE; Name: blood transfusion; Assigned to Arm(s): N/A
B: Arm Label: Prasugrel; Type: EXPERIMENTAL; Interventions: Drug: Prasugrel | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Prasugrel; Assigned to Arm(s): Prasugrel | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Transfusion Group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: transfusion therapy | Arm Label: Observation Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: transfusion therapy; Assigned to Arm(s): Transfusion Group
D: Arm Label: Blood Transfusion Trial Cohort; Type: ACTIVE_COMPARATOR; Interventions: Biological: Single blood transfusion | Arm Label: Standard Care Trial Cohort; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard care | Arm Label: Standard Care Observational Cohort; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard care | Intervention Type: BIOLOGICAL; Name: Single blood transfusion; Assigned to Arm(s): Blood Transfusion Trial Cohort | Intervention Type: BEHAVIORAL; Name: Standard care; Assigned to Arm(s): Standard Care Observational Cohort, Standard Care Trial Cohort

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To reduce episodes of first time stroke by 75 percent in children with sickle cell anemia by the administration of prophylactic transfusion therapy.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydroxyurea, Procedure: Phlebotomy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Red Cell Transfusions, Procedure: Iron Chelation | Intervention Type: PROCEDURE; Name: Red Cell Transfusions; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Iron Chelation; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Hydroxyurea; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Phlebotomy; Assigned to Arm(s): 1
B: Intervention Type: PROCEDURE; Name: blood transfusion; Assigned to Arm(s): N/A
C: Arm Label: Standard Therapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Treatment Arm; Type: EXPERIMENTAL; Interventions: Drug: Hydroxyurea | Intervention Type: DRUG; Name: Hydroxyurea; Assigned to Arm(s): Treatment Arm
D: Arm Label: Transfusion Group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: transfusion therapy | Arm Label: Observation Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: transfusion therapy; Assigned to Arm(s): Transfusion Group

Answer: B